U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07435701) titled 'Intraperitoneal SK-NK Cell Injection for Advanced Ovarian Cancer With Massive Ascites' on Feb. 21.
Brief Summary: This is a single-center, open-label, Phase I/II clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of SK-NK Cell Injection administered via intraperitoneal (IP) perfusion in patients with advanced ovarian cancer complicated by massive ascites .
The study focuses on patients who have failed standard therapies and are suffering from severe ascites. The treatment involves the direct infusion of allogeneic, highly activated Natural Killer (NK) cells (SK-NK) into the abdominal cavity .
Th...